SCHEMBL2127345

SCHEMBL2127345

COC(=O)Cc1ccc(OS(=O)(=O)C(F)(F)F)c(C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.43
CYP4A11 Q02928 1/20 0.43
GAA P10253 2/20 0.43
ALDH1A1 P00352 2/20 0.43
PDK2 Q15119 1/20 0.43
GFER P55789 1/20 0.43
CA5A P35218 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HSP90AB1 P08238 1/20 0.39
SLC7A5 Q01650 1/20 0.39
FFAR4 Q5NUL3 3/20 0.38
HPGD P15428 2/20 0.38
FFAR1 O14842 2/20 0.38
MAPT P10636 1/20 0.38
TSHR P16473 1/20 0.38
FFAR2 O15552 1/20 0.38
HTR7 P34969 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536191 0.90 RXRA (0.43) CYP4F2CYP4A11GAAALDH1A1PDK2
SCHEMBL14252745 0.88 SMN1; SMN2 (0.40) CYP4F2CYP4A11ALDH1A1CA5AL3MBTL1
SCHEMBL4842048 0.87 CA5A (0.58) CYP4F2CYP4A11GAAALDH1A1PDK2
SCHEMBL5738807 0.87 CA5A (0.51) CYP4F2CYP4A11GAAALDH1A1PDK2
SCHEMBL30154424 0.87 CYP4F2 (0.43) CYP4F2CYP4A11GAAALDH1A1PDK2
SCHEMBL2126108 0.87 CYP4F2 (0.43) CYP4F2CYP4A11GAAALDH1A1PDK2
SCHEMBL2125942 0.86 LMNA (0.43) CYP4F2CYP4A11GAAALDH1A1PDK2
SCHEMBL2124578 0.86 RXRA (0.43) CYP4F2CYP4A11GAAALDH1A1PDK2
SCHEMBL7420742 0.86 GAA (0.55) CYP4F2CYP4A11GAAALDH1A1PDK2
SCHEMBL17748399 0.83 CA5A (0.37) GAACA5AFFAR4FFAR1FFAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289520-A1 CHEMICAL COMPOUNDS 785 ASTRAZENECA AB (SE) 2012-11-15 US disclosed
US-20120289520-A1 CHEMICAL COMPOUNDS 785 ASTRAZENECA AB (SE) 2012-11-15 US disclosed
US-20120289520-A1 CHEMICAL COMPOUNDS 785 ASTRAZENECA AB (SE) 2012-11-15 US disclosed
US-8188092-B2 Substituted pyrazines as DGAT-1 inhibitors ASTRAZENECA AB (SE) 2012-05-29 US disclosed
US-8188092-B2 Substituted pyrazines as DGAT-1 inhibitors ASTRAZENECA AB (SE) 2012-05-29 US disclosed
US-8188092-B2 Substituted pyrazines as DGAT-1 inhibitors ASTRAZENECA AB (SE) 2012-05-29 US disclosed
EP-2443096-A1 PYRAZINE CARBOXAMIDES AS INHIBITORS OF DGAT1 AstraZeneca AB (SE) 2012-04-25 EP disclosed
US-20100324068-A1 CHEMICAL COMPOUNDS 785 ASTRAZENECA AB (SE) 2010-12-23 US disclosed
US-20100324068-A1 CHEMICAL COMPOUNDS 785 ASTRAZENECA AB (SE) 2010-12-23 US disclosed
US-20100324068-A1 CHEMICAL COMPOUNDS 785 ASTRAZENECA AB (SE) 2010-12-23 US disclosed
WO-2010146395-A1 PYRAZINE CARBOXAMIDES AS INHIBITORS OF DGAT1 ASTRAZENECA AB (SE) 2010-12-23 WO disclosed
WO-2010146395-A1 PYRAZINE CARBOXAMIDES AS INHIBITORS OF DGAT1 ASTRAZENECA AB (SE) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324068-A1 CHEMICAL COMPOUNDS 785 GPBAR1, DGAT1, GPR119 CYP4F2 382/4885CYP4A11 711/4885GAA 200/4885
US-20120289520-A1 CHEMICAL COMPOUNDS 785 DGAT1, DGAT2, SLC5A1 CYP4F2 583/4885CYP4A11 641/4885GAA 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.